Details of the anticancer efficacy of BD in several human malignancies using in vivo models
Cancer type | Model used | Dose | Duration | Measurement frequency | Route of administration | Observed effects | Mode of action | References |
---|---|---|---|---|---|---|---|---|
NSCLC | A549 cells in BALB/c-nu mice | 40 mg/kg/day | 15 days | Every 2 days | Intraperitoneal injection | ↓Tumour growth | ↑pJNK, ↑caspase 9 ↑Apoptosis; ↑LC3-II, ↑Autophagy | [28] |
Osteosarcoma | MNNG/HOS cells in BALC/c-nu mice | 2.5 mg/kg/2 days; 5.0 mg/kg/2 days | 12 days | Every 2 days | Intraperitoneal injection | ↓Tumour size↓Tumour weight | ↓pSTAT3, ↓MMP2 and MMP9, ↓Ki67 | [47] |
Hepatocellular carcinoma | Huh7 cells in BALC/c-nu mice | 0.75 mg/kg/day; 1.5 mg/kg/day | 10 days | Daily | Intravenous tail vein injection | ↓Tumour growth | ↑Proteasome, ↓Total β-catenin, ↓Active β-catenin, ↓JAG1, ↓NICD, ↑Apoptosis | [45] |
MMP2: matrix metalloproteinase-2 (gelatinase A); MMP9: matrix metallopeptidase 9 (gelatinase B)
The concept and design of this manuscript are conceived by ZWS and MG. ZWS, AKP, and MG wrote and revised the manuscript, presented the concept, created figures, tables. All authors have read the manuscript and agreed to the published version of the manuscript.
The authors declare that they have no conflicts of interest.
Not applicable.
Not applicable.
Not applicable.
Not applicable.
This work was supported by the Department of Biotechnology (DBT), under its Ramalingaswami Fellowship number BT/RLF/Re-entry/24/2014 and Science and Engineering Research Board under its ECRA scheme (SERB File No. ECR/2016/001519) award to Dr. Manoj Garg. The sponsor(s) have no role in designing, analysis, interpretation and writing.
© The Author(s) 2020.